🇺🇸 FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10227323

Glucosylceramide synthase inhibitors for the treatment of diseases

BIOMARIN PHARMACEUTICAL INC. · Granted Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10227312

Glucosylceramide synthase inhibitors for the treatment of diseases

BIOMARIN PHARMACEUTICAL INC. · Granted Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10226468

Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/m

Asana BioSciences, LLC · Granted Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10226452

Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments

The Regents of the University of California · Granted Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10221174

N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10221161

Inhibitors of plasma kallikrein

KalVista Pharmaceuticals Limited · Granted Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10214522

Anti-alphavbeta1 integrin inhibitors and methods of use

The Regents of the University of California · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10214509

Amino-substituted heterocyclic derivatives as sodium channel inhibitors

Almirall, S.A. · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10208040

Fused imidazo-piperidine JAK inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10206924

Small molecule inhibitors of EGFR and PI3K

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10202340

Glucosylceramide synthase inhibitors and therapeutic methods using the same

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Feb 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10202366

Methods of promoting wound healing using CRM1 inhibitors

Karyopharm Therapeutics Inc. · Granted Tue Feb 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10196424

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bow

Protagonist Therapeutics, Inc. · Granted Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10196393

JAK inhibitors containing a 4-membered heterocyclic amide

Theravance Biopharma R&D IP, LLC · Granted Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10196378

Inhibitors of BCR-ABL mutants and use thereof

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10195214

Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

Corcept Therapeutics Incorporated · Granted Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10189823

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10189784

N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of gluco

ACADEMISCH MEDISCH CENTRUM · Granted Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10183942

JAK kinase inhibitor compounds for treatment of respiratory disease

Theravance Biopharma R&D IP, LLC · Granted Tue Jan 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10183933

Isoindolinone inhibitors of phosphatidylinositol 3-kinase

Vertex Pharmaceuticals Incorporated · Granted Tue Jan 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10174018

Protein kinase inhibitors

Princeton Drug Discovery, Inc · Granted Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10173985

Aminoindazole derivatives as sodium channel inhibitors

Almirall, S.A. · Granted Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10172844

Use of CDK9 inhibitors to reduce cartilage degradation

The Regents of the University of California · Granted Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10172840

Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions there

VTV THERAPEUTICS LLC · Granted Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted